Patient, disease, and treatment characteristics (N = 31)
| Characteristic . | Data . |
|---|---|
| Age, median (range), y | 49 (22-77) |
| Females/males | 14/17 |
| Disease | |
| AML | 28 |
| MDS | 2 |
| CML (myeloid blast crisis) | 1 |
| Disease status | |
| Primary refractory | 16 |
| Refractory relapse | 15 |
| Blasts in PB pretreatment, median (range), % | 30 (0-100) |
| Blasts in BM pretreatment, median (range), % | 100 (6-100) |
| Prior treatment regimens, median (range) | 3 (1-7) |
| HCT CI comorbidity, median (range) | 2 (0-7) |
| ECOG score | |
| Median | 2 |
| 0/1/2/3 | 2/12/14/3 |
| ELN risk, low/intermediate/high | 0/4/27 |
| Time from diagnosis, median (range), mo | 11 (3-87) |
| Prior allogeneic BM transplantation | |
| Yes | 9 |
| No | 22 |
| Chemotherapy | |
| CLAM | 21 |
| Other chemotherapies | 10 |
| Clofarabine | 2 |
| Cytarabine/cladribine | 2 |
| Cytarabine/ruxolitinib | 1 |
| FLAG | 2 |
| IDAC | 1 |
| Liposomal daunorubicin/cytarabine | 1 |
| MEC | 1 |
| Characteristic . | Data . |
|---|---|
| Age, median (range), y | 49 (22-77) |
| Females/males | 14/17 |
| Disease | |
| AML | 28 |
| MDS | 2 |
| CML (myeloid blast crisis) | 1 |
| Disease status | |
| Primary refractory | 16 |
| Refractory relapse | 15 |
| Blasts in PB pretreatment, median (range), % | 30 (0-100) |
| Blasts in BM pretreatment, median (range), % | 100 (6-100) |
| Prior treatment regimens, median (range) | 3 (1-7) |
| HCT CI comorbidity, median (range) | 2 (0-7) |
| ECOG score | |
| Median | 2 |
| 0/1/2/3 | 2/12/14/3 |
| ELN risk, low/intermediate/high | 0/4/27 |
| Time from diagnosis, median (range), mo | 11 (3-87) |
| Prior allogeneic BM transplantation | |
| Yes | 9 |
| No | 22 |
| Chemotherapy | |
| CLAM | 21 |
| Other chemotherapies | 10 |
| Clofarabine | 2 |
| Cytarabine/cladribine | 2 |
| Cytarabine/ruxolitinib | 1 |
| FLAG | 2 |
| IDAC | 1 |
| Liposomal daunorubicin/cytarabine | 1 |
| MEC | 1 |
Data are number of patients, unless otherwise noted.
CLAM, cladribine, cytarabine, filgrastim, mitoxantrone; CML, chronic myeloid leukemia; ECOG, Eastern Cooperative Oncology Group; FLAG, fludarabine, high-dose cytarabine, filgrastim; HCT CI, hematopoietic cell transplant comorbidity index; IDAC, intermediate-dose cytarabine; MEC, mitoxantrone, etoposide, cytarabine.